You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

VEGFR2 TKI

Showing 1 - 25 of 1,853
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Clear Cell Metastatic Renal Cell Carcinoma Trial in France (Nivolumab, Ipilimumab, Pazopanib)

Completed
  • Clear Cell Metastatic Renal Cell Carcinoma
  • Bordeaux, France
  • +15 more
Apr 22, 2021

Breast Cancer, Triple-Negative Breast Cancer Trial in Guangzhou, Nanjing, Shanghai (Anti-PD-1 mAb, VEGFR2 Tyrosine Kinase

Recruiting
  • Breast Cancer
  • Triple-Negative Breast Cancer
  • Anti-PD-1 monoclonal antibody
  • VEGFR2 Tyrosine Kinase Inhibitor
  • Guangzhou, Guangdong, China
  • +2 more
Sep 24, 2022

Sarcoma Trial in Shanghai (Apatinib monotherapy)

Recruiting
  • Sarcoma
  • Apatinib monotherapy
  • Shanghai, Shanghai, China
    Ruijin Hospital Shanghai Jiao Tong University School of Medicine
May 18, 2022

Clear Cell Renal Cell Carcinoma?Resistance to Immunotherapy Trial in Shanghai (AK104(anti-PD-1/CTLA-4 bi-specific antibody

Recruiting
  • Clear Cell Renal Cell Carcinoma、Resistance to Immunotherapy
  • AK104（anti-PD-1/CTLA-4 bi-specific antibody ，intravenously）,lenvatinib（ targeted VEGFR 1-3、FGFR、PDGFRα， small molecule TKI，orally
  • Shanghai, Shanghai, China
    Shanghai Renji Hospital
Sep 12, 2023

Renal Cell Carcinoma Who Received First-Line Sunitinib

Completed
Has Results
  • Metastatic Renal Cell Carcinoma
  • Calgary, Alberta, Canada
    University of Calgary
Feb 19, 2021

PD-1 Immunotherapy, VEGFR-TKI, Sarcomatoid Carcinoma Trial in Shanghai (Camrelizumab Combined With Apatinib)

Recruiting
  • PD-1 Immunotherapy
  • +3 more
  • Camrelizumab Combined With Apatinib
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Mar 1, 2022

Metastatic Renal Cell Carcinoma, Good or Only One Adverse Prognostic Factor Intermediate Risk Per IMDC Score Trial in France

Not yet recruiting
  • Metastatic Renal Cell Carcinoma
  • Good or Only One Adverse Prognostic Factor Intermediate Risk Per IMDC Score
  • Combination PD-1/PD-L1 ICI + VEGFR-TKI
  • Treatment pause
  • Bayonne, France
  • +24 more
Aug 10, 2022

HER2+ Advanced Breast Cancer Patients Progressing on TKI Therapy Trial (Trastuzumab Emtansine for Injection, Pyrotinib Maleate

Not yet recruiting
  • HER2+ Advanced Breast Cancer Patients Progressing on TKI Therapy
  • Trastuzumab Emtansine for Injection
  • Pyrotinib Maleate Tablets
  • (no location specified)
Sep 30, 2022

Gastrointestinal Stromal Tumors Trial in Changsha (Apatinib Mesylate, Sunitinib, Imatinib dosage, Dasatinib, Reveratinib)

Recruiting
  • Gastrointestinal Stromal Tumors
  • Apatinib Mesylate
  • Sunitinib, Imatinib dosage, Dasatinib, Reveratinib
  • Changsha, Hunan, China
    Xiangya Hospital, Central South University
Mar 1, 2023

Dalpiciclib Combined With Third-generation EGFR-TKI in EGFR

Not yet recruiting
  • Non-small Cell Lung Cancer Confirmed by Histopathology or Cytology
  • +6 more
    • (no location specified)
    Aug 9, 2022

    Triple-negative Breast Cancer Trial in Shanghai (Pyrotinib with Capecitabine, AR inhibitor combined with everolimus(B1) or

    Recruiting
    • Triple-negative Breast Cancer
    • Pyrotinib with Capecitabine
    • +6 more
    • Shanghai, Shanghai, China
      Fudan University Shanghai Cancer Center
    Aug 8, 2022

    Gastric Cancer Trial in Jinan (SHR1210, Apatinib, S1)

    Recruiting
    • Gastric Cancer
    • Jinan, Shandong, China
      Qilu hospital of Shandong univertisy
    Mar 30, 2022

    NSCLC Trial in Seoul (BBT-176, Cetuximab)

    Recruiting
    • NSCLC
    • Seongnam-si, Gyeonggi-do, Korea, Republic of
    • +3 more
    Jan 6, 2023

    Non-Squamous NSCLC Trial in Shanghai (Sintilimab, IBI305, Pemetrexed)

    Recruiting
    • Non-Squamous Non-Small Cell Lung Cancer
    • Shanghai, Shanghai, China
      Shanghai Chest Hospital
    Sep 22, 2022

    Chordoma, Chemo Effect Trial in Beijing (camrelizumab and apatinib)

    Recruiting
    • Chordoma
    • Chemotherapy Effect
    • camrelizumab and apatinib
    • Beijing, Beijing, China
      BEIJING
    Nov 14, 2023

    Lung Cancer, Non Small Cell Lung Cancer Trial in Aurora (Amivantamab 1050mg, Amivantamab 1400mg, Amivantamab (to be determined))

    Not yet recruiting
    • Lung Cancer
    • Non Small Cell Lung Cancer
    • Amivantamab 1050mg
    • +2 more
    • Aurora, Colorado
    • +2 more
    Apr 25, 2023

    Colorectal Tumors Trial in Wuhan (Surufatinib)

    Recruiting
    • Colorectal Neoplasms
    • Chohort 1: Surufatinib
    • +2 more
    • Wuhan, Hubei, China
      Hubei Cancer Hospital
    Nov 5, 2022

    Diabetic Macular Edema Trial (EYP-1901, Aflibercept 2Mg/0.05Ml Inj,Oph)

    Not yet recruiting
    • Diabetic Macular Edema
    • (no location specified)
    Oct 19, 2023

    Renal Cell Carcinoma Trial in Worldwide (Nivolumab, Bempegaldesleukin, Axitinib)

    Active, not recruiting
    • Renal Cell Carcinoma
    • Nivolumab
    • +2 more
    • Springdale, Arkansas
    • +33 more
    Nov 22, 2022

    Lung Cancer Trial in Boston (EGF816, Gefitinib)

    Active, not recruiting
    • Lung Cancer
    • Boston, Massachusetts
      Massachusetts General Hospital
    Jan 21, 2022

    Refractory Soft Tissue Sarcomas Trial run by the NCI (Cabozantinib)

    Active, not recruiting
    Has Results
    • Refractory Soft Tissue Sarcomas
    • Bethesda, Maryland
      National Institutes of Health Clinical Center, 9000 Rockville Pi
    Dec 5, 2022

    Metastatic Colorectal Cancer, mCRC Trial in Guangzhou (Tislelizumab & Fruquintinib)

    Not yet recruiting
    • Metastatic Colorectal Cancer
    • mCRC
    • Tislelizumab & Fruquintinib
    • Guangzhou, Guangdong, China
    • +1 more
    Jan 25, 2023

    Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma, Recurrent Adenoid Cystic Carcinoma Trial in Boston (CB-103,

    Not yet recruiting
    • Adenoid Cystic Carcinoma
    • +2 more
    • Boston, Massachusetts
      Dana Farber Cancer Institute
    Mar 14, 2023

    Neovascular Age-related Macular Degeneration, Diabetic Macular Edema Trial in Brisbane (D-4517.2)

    Completed
    • Neovascular Age-related Macular Degeneration
    • Diabetic Macular Edema
    • Brisbane, Queensland, Australia
      Nucleus Network (Brisbane)
    Sep 19, 2022

    Chronic Myeloid Leukemia Trial in Germany, Netherlands (TKI discontinuation, nilotinib)

    Active, not recruiting
    • Chronic Myeloid Leukemia
    • Freiburg, Baden-Württemberg, Germany
    • +14 more
    Nov 4, 2021